Natural Beauty Bio-Technology (0157) AI Stock Analysis

• Market Cap: $1.08B
• Dividend Yield: N/A
• Average Volume (3M): 20.00K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.05
• Revenue Growth: 39.29%
• EPS Growth: -71.82%
• Country: HK
• Employees: 542
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Household & Personal Products
• EPS (TTM): N/A
• Shares Outstanding: 2,002,101,000
• 10 Day Avg. Volume: 5,000
• 30 Day Avg. Volume: 20,000
• PEG Ratio: -0.02
• Price to Book (P/B): 2.17
• Price to Sales (P/S): 2.75
• P/FCF Ratio: -17.67
• Enterprise Value/Market Cap: 0.99
• Enterprise Value/Revenue: 3.04
• Enterprise Value/Gross Profit: 5.63
• Enterprise Value/Ebitda: -16.40
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 41 Neutral
• Price Target: HK$0.50 ▼(-7.41% Downside)

The overall stock score is primarily impacted by significant financial challenges, including declining revenue and profitability, increased leverage, and cash flow difficulties. Technical analysis shows neutral indicators, while valuation metrics are poor due to negative earnings and lack of dividends.

Natural Beauty Bio-Technology Business Overview & Revenue Model

Company Description

Natural Beauty Bio-Technology Limited, an investment holding company, offers skin care products and services in in the People's Republic of China, Taiwan, and internationally. The company manufactures and sells skin care, beauty, aroma-therapeutic, cosmetics, health supplements, and make-up products under the Natural Beauty brand. It also offers skin treatment, beauty and spa, medical cosmetology, skin care consulting, and beauty consulting and training services. In addition, the company's spas provide hydrotherapy, facial treatment, body care, and skin care analysis services. Further, it engages in the wholesale of skin care and beauty products. The company was founded in 1976 and is based in Wan Chai, Hong Kong.

How the Company Makes Money

Natural Beauty Bio-Technology generates revenue through multiple streams, primarily from the sale of its proprietary beauty and personal care products. The company has established partnerships with retail chains and online platforms, allowing for widespread distribution of its products. Additionally, it may earn income through private label manufacturing for other brands, leveraging its biotechnology capabilities to create customized formulations. Significant factors contributing to its earnings include increasing consumer demand for natural and eco-friendly products, as well as trends favoring sustainable beauty solutions.

Natural Beauty Bio-Technology Financial Statement Overview

Summary

Natural Beauty Bio-Technology faces significant financial challenges. Revenue and profitability have declined, impacting income statement metrics negatively. The balance sheet shows increasing leverage and decreasing equity ratios, signaling potential financial instability. Cash flow issues further exacerbate the company's difficulties, indicating strained liquidity and operational inefficiencies.

Income Statement

The company has experienced a decline in revenue from 2021 to 2024, indicating negative growth. Gross profit margins have decreased while net profit margins are negative, showing a lack of profitability. EBIT and EBITDA margins have worsened significantly, marking a challenging operating environment.

Balance Sheet

The debt-to-equity ratio has increased over the years, reflecting rising leverage, yet it remains manageable. The equity ratio has decreased slightly, suggesting a decline in asset financing through equity. Return on equity is negative due to net losses, which is a concern for profitability.

Cash Flow

The company has seen a negative trend in free cash flow, with significant declines from 2021 to 2024. The operating cash flow to net income ratio is negative, indicating operational challenges. Free cash flow to net income ratio also reflects cash flow difficulties, hindering financial flexibility.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	353.65M	336.01M	335.88M	487.81M	410.67M
Gross Profit	202.33M	200.34M	165.33M	281.80M	217.22M
EBITDA	-65.50M	22.91M	15.09M	85.23M	47.90M
Net Income	-103.61M	-15.11M	-30.47M	35.26M	7.76M
Balance Sheet
Total Assets	772.93M	882.58M	883.53M	937.16M	840.77M
Cash, Cash Equivalents and Short-Term Investments	116.51M	166.81M	168.61M	197.08M	165.61M
Total Debt	212.13M	186.29M	143.48M	129.07M	75.02M
Total Liabilities	325.34M	308.06M	286.07M	279.24M	229.54M
Stockholders Equity	447.59M	574.52M	597.46M	657.92M	611.23M
Cash Flow
Free Cash Flow	-54.96M	-47.39M	-35.98M	4.67M	-43.77M
Operating Cash Flow	-13.75M	21.72M	8.33M	42.78M	30.09M
Investing Cash Flow	-40.17M	-67.61M	-38.77M	-31.21M	-48.89M
Financing Cash Flow	15.34M	42.63M	13.21M	10.42M	28.06M

Natural Beauty Bio-Technology Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.54
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0157, the sentiment is Positive. The current price of 0.54 is above the 20-day moving average (MA) of 0.54, below the 50-day MA of 0.55, and above the 200-day MA of 0.51, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 48.08 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:0157.

Natural Beauty Bio-Technology Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2145	74 Outperform	HK$39.80B	39.36	39.62%	2.34%	20.78%	18.37%
1925	74 Outperform	HK$445.55M	4.56	17.17%	8.18%	21.99%	11.36%
2177	63 Neutral	HK$444.60M	16.69	3.32%	18.25%	-9.26%	435.33%
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
3332	56 Neutral	HK$664.25M	21.93	3.92%	―	-0.92%	-71.88%
6993	47 Neutral	HK$17.94B	―	-6.08%	4.53%	2.79%	-170.67%
0157	41 Neutral	$1.08B	―	-12.38%	―	39.29%	-71.82%

Natural Beauty Bio-Technology Corporate Events

Natural Beauty Bio-Technology Unveils Interim Results and New Share Schemes

Natural Beauty Bio-Technology Limited has announced its unaudited consolidated interim results for the first half of 2025, alongside plans to adopt a new share option scheme and amend its Share Award Scheme II. The proposed 2025 Share Option Scheme aims to incentivize and align the interests of eligible participants with the company, while the amendments to the Share Award Scheme II will allow the issuance of new shares to a broader group, including distributors, pending shareholder and regulatory approvals.

Natural Beauty Bio-Technology Announces Change in Company Secretary

Natural Beauty Bio-Technology Limited has announced a change in its company secretary and authorized representative, effective August 5, 2025. Ms. Kwok Yin Ting has resigned from her position, and Ms. Lee Mei Yi, with over 25 years of experience in company secretarial services, will take over the role. This change is expected to enhance the company’s compliance and governance capabilities, given Ms. Lee’s extensive experience and qualifications in the field.